Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (NASDAQ: EXAS) is frequently in the news as a leading provider of cancer screening and diagnostic tests. Company announcements highlight developments across stool-based colorectal cancer screening, multi-cancer early detection, liver cancer surveillance, and precision oncology genomics. News coverage often reflects new clinical data, product launches, collaborations, and corporate transactions that shape the company’s role in cancer diagnostics.
Investors and clinicians following EXAS news can expect updates on the performance and adoption of the Cologuard and Cologuard Plus colorectal cancer screening tests, including real‑world adherence data and modeling studies that examine benefit‑to‑burden trade‑offs. Exact Sciences also reports on progress with its Cancerguard multi‑cancer early detection blood test, including study results from large prospective trials designed to support broader clinical use.
Another recurring theme in Exact Sciences news is the expansion of its precision oncology and surveillance portfolio. Releases describe pivotal and prospective studies of the Oncoguard Liver blood test for hepatocellular carcinoma surveillance, the Oncodetect molecular residual disease test in high‑risk breast cancer and other solid tumors, and the OncoExTra comprehensive genomic profiling assay for advanced cancers. These updates often come from major scientific meetings and include details on sensitivity, specificity, and prognostic performance.
Corporate and financial news items for EXAS include quarterly earnings releases, updated revenue and adjusted EBITDA guidance, participation in investor conferences, and strategic agreements such as the collaboration and license arrangement with Freenome for blood‑based colorectal cancer screening tests. A notable development disclosed in both press releases and SEC filings is the definitive agreement under which Abbott Laboratories plans to acquire Exact Sciences, subject to stockholder and regulatory approvals and other customary conditions.
This news page aggregates such announcements, offering a single place to review Exact Sciences’ latest clinical, product, financial, and transaction-related updates over time.
Exact Sciences Corp. (Nasdaq: EXAS) reported fourth-quarter 2020 revenue of $466.3 million, with full-year revenue reaching $1.49 billion. Q4 screening revenue grew by 9% to $249.7 million, while COVID-19 testing contributed $99.1 million. However, the company faced a net loss of $436.8 million, or $(2.79) per share, compared to a net income of $78.0 million last year. The acquisition of Base Genomics resulted in a $412.6 million research and development charge. Cash reserves stood at $1.84 billion.
Exact Sciences Corp. (Nasdaq: EXAS) announced its acquisition of Ashion Analytics from The Translational Genomics Research Institute (TGen). Ashion, a CLIA-certified sequencing lab, will enhance Exact's precision oncology portfolio, particularly in minimal residual disease (MRD) testing. The acquisition includes a 10-year research collaboration with TGen and City of Hope to develop advanced MRD testing. This partnership aims to expedite bringing innovative genomic solutions to cancer treatment, leveraging Ashion's expertise and TARDIS technology.
Exact Sciences Corp. (Nasdaq: EXAS) is set to release its fourth quarter 2020 financial results on February 16, 2021, after U.S. market close. Management will host a webcast and conference call at 5 p.m. EST to discuss the financial results and business progress. The company is a leading provider of cancer screening and diagnostic tests, with an emphasis on improving patient care through products like Cologuard and Oncotype DX. For further details, visit their official website.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in several upcoming investor conferences in February 2021, inviting investors to join via webcast. Key events include:
- BTIG Virtual MedTech Conference on February 18, 2021 at 10:30 a.m. EST
- Citi Healthcare Services Conference on February 24, 2021 at 9:50 a.m. EST
- SVB Leerink Global Healthcare Conference on February 25, 2021 at 1:40 p.m. EST
Investors can access the webcasts on the company's investor relations webpage.
Exact Sciences Corp. (Nasdaq: EXAS) has acquired a worldwide exclusive license for TARDIS technology from TGen, enhancing its position in precision oncology. This innovative approach enables noninvasive detection of minimal residual disease, particularly for patients with small amounts of tumor DNA post-treatment. TARDIS technology demonstrated up to a 100-fold improvement in sensitivity for detecting circulating tumor DNA. This collaboration aims to improve cancer patient outcomes through advanced diagnostics, leveraging Exact Sciences' established expertise with products like Cologuard and Oncotype DX.
Exact Sciences Corp. (Nasdaq: EXAS) announced findings published in Cancer Prevention Research, highlighting the effectiveness of Cologuard in screening average-risk adults aged 45-49 for colorectal cancer. The study revealed a test specificity of 95.2% for participants without advanced precancerous lesions. The research supports Cologuard's role in mitigating risks and costs associated with unnecessary procedures. With colorectal cancer being the second leading cause of cancer death in the U.S., this data emphasizes the importance of early detection, especially as cases in younger adults have significantly increased.
Exact Sciences Corp. (Nasdaq: EXAS) anticipates reporting a 2020 fourth-quarter revenue of $464.5 million to $467.5 million. Expected Screening revenue is projected between $249 million and $250 million, marking a 9% increase year-over-year. The company anticipates Precision Oncology revenue of $117 million to $118 million and COVID-19 testing revenue between $98.5 million and $99.5 million. While these estimates are promising, they are preliminary and subject to change pending completion of the financial statements.
Exact Sciences Corp. (Nasdaq: EXAS) has finalized its acquisition of Thrive Earlier Detection Corp., a significant move towards establishing blood-based multi-cancer screening as a standard practice. CEO Kevin Conroy emphasized the strategic importance of this acquisition in revolutionizing cancer diagnostics and improving early detection and treatment options for patients. The company is committed to advancing its product pipeline, building on successes like Cologuard and Oncotype DX. This acquisition is aimed at addressing some of the most lethal cancers and enhancing patient care.
Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 p.m. EST. Investors can join the discussion via webcast, accessible through the investor relations section of Exact Sciences' website.
This leading cancer diagnostics company aims to advance patient care and tackle deadly cancers through innovative solutions. For more details, visit exactsciences.com.
Exact Sciences Corp. (NASDAQ: EXAS) presented new data at the 2020 San Antonio Breast Cancer Symposium (SABCS), emphasizing the Oncotype DX Breast Recurrence Score test's role in personalizing early breast cancer treatment. The ADAPT study revealed that patients with clinically high-risk node-negative or node-positive disease can forgo chemotherapy based on favorable Recurrence Score results, achieving a 5-year distant disease-free survival rate of 96%. A new RSClin tool will provide individualized estimates for chemotherapy benefits, enhancing treatment discussions. The meta-analysis integrates findings from over 10,000 patients.